Competitive landscape
Drugs aimed at the same indication, from approved to preclinical.
14 drugs for “Prostate Cancer”
Approved 1
- CapivasertibASTRAZENECA PLCHormone-Sensitive Prostate Cancer; Prostate Cancer
Phase 3 13
- AAA617NOVARTIS AGOligometastatic Prostate Cancer (OMPC)
- AAA817NOVARTIS AGProstate Cancer
- Actinium zadavotide guraxetanASTRAZENECA PLCMetastatic Castration-resistant Prostate Cancer
- BNT324BioNTech SEMetastatic Castration-resistant Prostate Cancer
- CTT1057NOVARTIS AGProstate Cancer
- Gallium gozetotideNOVARTIS AGOligometastatic Prostate Cancer (OMPC)
- Ifinatamab deruxtecanMerck & Co., Inc.Prostate Cancer
- MevrometostatPFIZER INCHormone Sensitive Prostate Cancer; Metastatic Castration Sensitive Prostate Cancer (mCSPC); Prostate Cancer
- OpevesostatMerck & Co., Inc.Metastatic Castration-resistant Prostate Cancer (mCRPC); Prostate Cancer Metastatic
- PiflufolastatNOVARTIS AGOligometastatic Prostate Cancer (OMPC)
- RinzimetostatOric Pharmaceuticals, Inc.Metastatic Castration Resistant Prostate Cancer
- SaruparibASTRAZENECA PLCMetastatic Castration-Sensitive Prostate Cancer; Metastatic Hormone-Sensitive Prostate Cancer (mHSPC); Prostate Cancer
- XaluritamigAMGEN INCMetastatic Castration-resistant Prostate Cancer
Drugs whose recorded indications name this term, by development stage. Indications come from registries and labels, so a drug can appear under related terms.